Clinical trials referral resource: Current clinical trials of epothilone B analog (BMS-247550)

被引：0
|
作者：
Colevas, AD [1 ]
West, PJ [1 ]
Cheson, BD [1 ]
机构：
[1] NCI, Bethesda, MD 20892 USA
来源：
ONCOLOGY-NEW YORK | 2001年 / 15卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1168 / +
页数：5
相关论文
共 50 条
  • [1] Treatment of recurrent cervical adenocarcinoma with BMS-247550, an epothilone B analog
    Agrawal, M
    Edgerly, M
    Fojo, T
    Kotz, H
    GYNECOLOGIC ONCOLOGY, 2003, 90 (01) : 96 - 99
  • [2] Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study
    McDaid, HM
    Mani, S
    Shen, HJ
    Muggia, F
    Sonnichsen, D
    Horwitz, SB
    CLINICAL CANCER RESEARCH, 2002, 8 (07) : 2035 - 2043
  • [3] A phase I clinical trial of BMS-247550 (NSC 710428), an epothilone B analog, in patients with refractory neoplasms.
    Fojo, AT
    Kotz, H
    Abraham, J
    Agrawal, M
    Bates, SE
    Balis, F
    Widemann, B
    Bakke, S
    Edgerly, M
    Rutt, A
    Damle, B
    Sonnichsen, D
    Lebwohl, D
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3809S - 3809S
  • [4] Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer
    Low, JA
    Wedam, SB
    Lee, JJ
    Berman, AW
    Brufsky, A
    Yang, SX
    Poruchynsky, MS
    Steinberg, SM
    Mannan, N
    Fojo, T
    Swain, SM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (12) : 2726 - 2734
  • [5] A phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days
    Zhuang, SH
    Agrawal, M
    Edgerly, M
    Bakke, S
    Kotz, H
    Thambi, P
    Rutt, A
    Balis, FM
    Bates, S
    Fojo, T
    CANCER, 2005, 103 (09) : 1932 - 1938
  • [6] A Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) in Patients with Metastatic Melanoma
    Ott, Patrick A.
    Hamilton, Anne
    Jones, Amanda
    Haas, Naomi
    Shore, Tsiporah
    Liddell, Sandra
    Christos, Paul J.
    Doyle, L. Austin
    Millward, Michael
    Muggia, Franco M.
    Pavlick, Anna C.
    PLOS ONE, 2010, 5 (01):
  • [7] Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors
    Mani, S
    McDaid, H
    Hamilton, A
    Hochster, H
    Cohen, MB
    Khabelle, D
    Griffin, T
    Lebwohl, DE
    Liebes, L
    Muggia, F
    Horwitz, SB
    CLINICAL CANCER RESEARCH, 2004, 10 (04) : 1289 - 1298
  • [8] Clinical Trials Referral Resource - Current clinical trials of fenretinide
    Swerdlow, RD
    Zwiebel, JA
    Gravell, AE
    Cheson, BD
    ONCOLOGY-NEW YORK, 2001, 15 (12): : 1595 - +
  • [9] Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer
    Thomas, Eva
    Tabernero, Josep
    Fornier, Monica
    Conte, Pierfranco
    Fumoleau, Pierre
    Lluch, Ana
    Vahdat, Linda T.
    Bunnell, Craig A.
    Burris, Howard A.
    Viens, Patrice
    Baselga, Jose
    Rivera, Edgardo
    Guarneri, Valentina
    Poulart, Valerie
    Klimovsky, Judith
    Lebwohl, David
    Martin, Miguel
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (23) : 3399 - 3406
  • [10] Efficacy and safety of ixabepilone (BMS-247550), a novel epothilone B analogue
    Villanueva, Cristian
    Dufresne, Armelle
    Pivot, Xavier
    Viel, Erika
    BULLETIN DU CANCER, 2008, 95 (02) : 197 - 204
12345